One of the most frequently asked questions about Selank is how long its effects last and for what period the peptide remains active in the body. However, pharmacokinetic studies in humans that would definitively determine Selank's half-life, its blood concentration profile, or its exact elimination time have not yet been published. Most of the available research has focused on its biological and neurological effects, rather than its pharmacokinetic properties.
However, it is known that Selank was designed to remain active for longer than its natural precursor, tuftsin. The addition of the Pro-Gly-Pro fragment helps protect the peptide from rapid enzymatic breakdown, allowing its biological activity to be maintained for a longer period compared to naturally occurring tuftsin peptides [1,2].
Experimental studies have shown that Selank can induce biological effects that persist beyond the duration of its administration. For example, animal studies examining anxiety-related behaviours demonstrated a sustained anxiolytic effect throughout the entire four-week treatment period, suggesting that regular administration may provide stable biological activity over time [3]. Research into GABA receptor modulation, neurotransmitter regulation, and BDNF expression also indicates that Selank may initiate secondary biological changes that last longer than the peptide itself remains in circulation [2,4].
Since formal pharmacokinetic studies are still lacking, it is currently impossible to accurately determine for how many hours or days Selank remains in the blood or tissues. For this reason, any specific claims regarding duration of action or half-life should be treated with caution unless supported by direct human pharmacokinetic data.
How long does Selank stay in the body?
Currently, no human studies have been published determining how long Selank remains detectable in the body. Like many other peptides, Selank is likely subject to enzymatic breakdown into smaller peptide fragments and amino acids after administration. However, the exact elimination time has not been definitively determined in clinical trials.
It is also worth distinguishing the physical presence of the peptide from the duration of its biological effects. Even after Selank has been metabolised, processes related to neurotransmitters, neurotrophic factors, stress response, and gene expression may persist for a longer time [2,4].
For this reason, researchers usually focus more attention on the duration of biological activity than on attempting to estimate the unconfirmed time of elimination.
Half-life of Selank
The precise half-life of Selank has not yet been described in the published scientific literature concerning humans. Unlike many approved pharmaceutical drugs, Selank has not undergone extensive pharmacokinetic studies within large international clinical programmes.
However, it is known that it has been deliberately modified to increase stability relative to tuftsin. The addition of the Pro-Gly-Pro sequence was intended to slow down enzyme degradation and prolong the biological activity of the peptide [1]. However, no peer-reviewed study has currently reported a confirmed value for plasma half-life.
Therefore, any numerical estimates of Selank's half-life available online should be interpreted with caution if not supported by direct pharmacokinetic studies.
How quickly does Selank start working?
Selank's onset of action appears to depend on the specific biological effect being assessed. Some laboratory studies suggest that Selank may influence neurotransmitter systems and receptor activity relatively quickly after administration, whereas clinically significant benefits may develop over several days or weeks.
Research analysing Selank's interaction with GABA receptors has demonstrated direct modulation of GABAergic signalling pathways, suggesting that some of the neurochemical effects may arise shortly after administration [2]. Studies into enkephalin metabolism have also shown that Selank can inhibit enzymes responsible for their breakdown, providing another mechanism that allows for early biological effects to occur [5].
Clinical studies provide further information. In studies involving individuals with generalised anxiety disorder and neurasthenia, Selank demonstrated a measurable anxiolytic effect during therapy and achieved efficacy comparable to medazepam [6]. However, the study did not specify the exact time of onset of action, measured in minutes or hours.
Animal studies provide further clues. In long-term anxiety models, a significant reduction in anxiety-related behaviours was observed from the second day of therapy, with benefits persisting throughout the study period [3]. These findings suggest that while some neurochemical changes may occur relatively quickly, more noticeable behavioural effects may develop with regular use.
Does Selank work immediately?
Current data do not indicate that Selank acts immediately in the same way as fast-acting sedatives. In contrast to benzodiazepines, which directly bind to the benzodiazepine sites of GABA-A receptors and can induce rapid effects, Selank acts through broader neuroregulatory mechanisms involving GABA signalling, endogenous opioid peptides, neurotrophic factors, and pathways related to the immune system [2,5].
As these mechanisms are based on the body's regulatory and adaptive processes, some effects may develop gradually rather than causing an immediate and pronounced reaction. Available data suggest that the benefits associated with Selank may increase with continued use.
How quickly does Selank work?
Based on current research, Selank appears to be capable of affecting neurochemical pathways relatively quickly after administration. However, outcomes such as anxiolysis, improved emotional balance, or support for cognitive functions may require regular use for several days or a longer observation period [2–6].
The exact time to observe effects may depend on factors such as route of administration, dosage, duration of therapy, individual physiology, and the biological parameter being assessed. A widely accepted onset time has not yet been established.
Conclusions
Available research indicates that Selank was developed to provide greater stability than its natural precursor and may induce biological effects that persist beyond the administration period itself. However, the precise half-life, elimination time, and duration of the peptide's presence in the body have not yet been fully characterised in human studies.
Current data suggest that Selank may relatively quickly influence neurochemical pathways, while more significant effects related to anxiety, stress resistance, and cognitive function may develop gradually over time. Further pharmacokinetic and clinical studies will be needed to more accurately determine how long Selank remains active and how quickly its effects appear.
Disclaimer
This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Selank remains a research peptide in many countries, and its pharmacokinetic properties have not yet been fully determined in human clinical trials. The information presented is a summary of findings from human and animal studies and mechanistic research and should not be interpreted as claims regarding the efficacy, duration of action, or period of activity of the peptide.
For research purposes only: Selank products supplied by Semax Polska are intended solely for laboratory and scientific research. They are not approved for human consumption, medical use, diagnosis, treatment or the prevention of disease. All research materials should be used in accordance with applicable regulations and the principles of good laboratory practice.
References
[1] Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Antiviral Properties of Structural Fragments of the Peptide Selank. Doklady Biological Sciences, 431, 79–82. https://doi.org/10.1134/S0012496610020031
[2] Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. F. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[3] Czabak-Garbacz, R., Cygan, B., Wolański, Ł., & Kozlovsky, I. (2006). Influence of Long-Term Treatment with Tuftsin Analogue TP-7 on Anxiety-Phobic States and Body Weight. Pharmacological Reports, 58(4), 562–567. PMID: 16963804.
[4] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.
[5] Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Y. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274
[6] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalised Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/